Gen2 applies human stem cell models of neurodegenerative disease to understand the mechanisms by which these diseases spread through the nervous system as the basis for developing innovative therapeutics to slow and halt disease progression.

Gen2’s lead program, Gen2B, has developed novel antibody therapeutics that target uptake of extracellular toxic forms of microtubule-associated protein tau (Tau) to slow progression of neurodegenerative diseases such as Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy. Gen2’s lead anti-tau antibodies specifically target toxic tau, avoiding abundant normal non-toxic tau, in order to increase target engagement and therapeutic efficacy.

Our Science